Skip to content

The effect of ferric citrate on heart failure

The effect of ferric citrate on heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041220137
Enrollment
162
Registered
2023-02-08
Start date
2023-10-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure Heart failure

Interventions

Intervention group: ferric citrate 250mg 2 tablets orally every day for 16 weeks Control group: No treatment. If hemoglobin is less than 10g/dL, oral iron supplementation other than ferric citrate. Ir

Sponsors

Hamano Takayuki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age 20 years or older 2.Heart failure with left ventricular ejection fraction less than 50% 3.Iron deficiency, defined by ferritin less than 100 ng/mL or ferritin less than 300 ng/mL and transferrin saturation less than 20% 4. Mild anemia (Hb>=10g/dL and Hb<13g/dL in men, Hb<12g/dL in women 5.Those who can perform cardiopulmonary exercise test 6.Those on the stable dose of medications for heart failure including RAS inhibitors, SGLT2 inhibitors,beta-blockers, or ARNI for more than 2 months 7. Those who consented for participation in this research

Exclusion criteria

Exclusion criteria: 1.Hemoglobin less than 10g/dL, decrease in hemoglobin more than 1g per month 2.History of gastrointestinal bleeding, surgery, or transfusion within 3 months 3.Expecting surgery in next 4 months 4.Pregnant or lactating women and women who intend to be pregnant 5.Those who are already receiving oral or intravenous iron treatment 6.Those who have experienced serious adverse events by oral iron in the past 7.Chemotherapy for malignancy 8.Hematological malignancy including myelodysplastic syndrome 9.Those on dialysis 10. Those on erythropoiesis stimulating agents or hypoxia-inducible factor prolyl hydroxylase inhibitors 11.Those who were considered to be inappropriate to participate in the study by treating physicians

Design outcomes

Primary

MeasureTime frame
% predicted peak VO2 measured by cardiopulmonary exercise testing

Secondary

MeasureTime frame
KCCQ score, left ventricular ejection fraction, BNP, ferritin, transferrin saturation, Hb, MCV, MCH, MCHC, RDW, hepcidin, BUN, creatinine, proteinuria

Contacts

Public ContactShuichi Kitada

Nagoya City University Hospital

s1kitada@med.nagoya-cu.ac.jp+81-52-853-8221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026